We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319623

CAS#: 476436-68-7

Description: Naveglitazar, also known as LY 519818, LY 9818, is a peroxisome proliferator-activated receptor (PPAR) modulator, had been in phase II clinical trials for the once-daily oral treatment of type 2 diabetes, however, no recent development for this indication has been reported.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-09-22. Prices are subject to change without notice.

Naveglitazar is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 319623
Name: Naveglitazar
CAS#: 476436-68-7
Chemical Formula: C25H26O6
Exact Mass: 422.1729
Molecular Weight: 422.477
Elemental Analysis: C, 71.07; H, 6.20; O, 22.72

Synonym: LY519818; LY-519818; LY 519818; LY-9818; LY9818; LY 9818; CCRIS 9448; Naveglitazar.

IUPAC/Chemical Name: (S)-2-methoxy-3-(4-(3-(4-phenoxyphenoxy)propoxy)phenyl)propanoic acid


InChi Code: InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and
bladder cancer: lessons from animal studies. J Environ Sci Health C Environ
Carcinog Ecotoxicol Rev. 2012;30(4):368-402. doi: 10.1080/10590501.2012.735519.
Review. PubMed PMID: 23167631.

2: Long GG, Reynolds VL, Dochterman LW, Ryan TE. Neoplastic and non-neoplastic
changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR
alpha/gamma agonist. Toxicol Pathol. 2009 Oct;37(6):741-53. doi:
10.1177/0192623309343775. Epub 2009 Aug 21. PubMed PMID: 19700659.

3: Ahlawat P, Srinivas NR. Allometric prediction of the human pharmacokinetic
parameters for naveglitazar. Eur J Drug Metab Pharmacokinet. 2008
Jul-Sep;33(3):187-90. PubMed PMID: 19007045.

4: Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR.
Urothelial carcinogenesis in the urinary bladder of rats treated with
naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for
urolithiasis as an inciting event. Toxicol Pathol. 2008 Feb;36(2):218-31. doi:
10.1177/0192623307311757. PubMed PMID: 18474944.

5: Yi P, Hadden CE, Annes WF, Jackson DA, Peterson BC, Gillespie TA, Johnson JT.
The disposition and metabolism of naveglitazar, a peroxisome
proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice,
rats, and monkeys. Drug Metab Dispos. 2007 Jan;35(1):51-61. Epub 2006 Sep 29.
PubMed PMID: 17012539.